Literature DB >> 30447930

The role of endothelial colony forming cells in kidney cancer's pathogenesis, and in resistance to anti-VEGFR agents and mTOR inhibitors: A speculative review.

Valentina Poletto1, Vittorio Rosti2, Marco Biggiogera3, Germano Guerra4, Francesco Moccia5, Camillo Porta6.   

Abstract

Renal cell carcinoma (RCC) is highly dependent on angiogenesis, due to the overactivation of the VHL/HIF/VEGF/VEGFRs axis; this justifies the marked sensitivity of this neoplasm to antiangiogenic agents which, however, ultimately fail to control tumor growth. RCC also frequently shows alterations in the mTOR signaling pathway, and mTOR inhibitors have shown a similar pattern of initial activity/late failure as pure antiangiogenic agents. Understanding mechanisms of resistance to these agents would be key to improve the outcome of our patients. Circulating endothelial cells are a family of mainly bone marrow-derived progenitors, which have been postulated to be responsible of the reactivation of angiogenesis in different tumors. In this review, we shall discuss the complex nature and function of these cells, the evidence pro and contra their contribution to tumor vascularization, especially as far as RCC is concerned, and their possible role in determining resistance to presently available treatments.
Copyright © 2018. Published by Elsevier B.V.

Entities:  

Keywords:  Antiangiogenic agents; Circulating endothelial cells; Endothelial colony forming cells; Renal cell carcinoma; Resistance; mTOR inhibitors

Mesh:

Substances:

Year:  2018        PMID: 30447930     DOI: 10.1016/j.critrevonc.2018.09.005

Source DB:  PubMed          Journal:  Crit Rev Oncol Hematol        ISSN: 1040-8428            Impact factor:   6.312


  8 in total

1.  ITPKA1 Promotes Growth, Migration and Invasion of Renal Cell Carcinoma via Activation of mTOR Signaling Pathway.

Authors:  Xiang Zhu; An Xu; Yang Zhang; Nan Huo; Rui Cong; Luyuan Ma; Zhong Chu; Zhi Tang; Xiaofeng Kang; Shaozhong Xian; Xiaojie Xu
Journal:  Onco Targets Ther       Date:  2020-10-15       Impact factor: 4.147

Review 2.  Endothelial TRPV1 as an Emerging Molecular Target to Promote Therapeutic Angiogenesis.

Authors:  Sharon Negri; Pawan Faris; Vittorio Rosti; Maria Rosa Antognazza; Francesco Lodola; Francesco Moccia
Journal:  Cells       Date:  2020-05-27       Impact factor: 6.600

3.  PLEKHO1 knockdown inhibits RCC cell viability in vitro and in vivo, potentially by the Hippo and MAPK/JNK pathways.

Authors:  Zi Yu; Qiang Li; Gejun Zhang; Chengcheng Lv; Qingzhuo Dong; Cheng Fu; Chuize Kong; Yu Zeng
Journal:  Int J Oncol       Date:  2019-05-30       Impact factor: 5.650

Review 4.  Endothelial Ca2+ Signaling, Angiogenesis and Vasculogenesis: just What It Takes to Make a Blood Vessel.

Authors:  Francesco Moccia; Sharon Negri; Mudhir Shekha; Pawan Faris; Germano Guerra
Journal:  Int J Mol Sci       Date:  2019-08-14       Impact factor: 5.923

Review 5.  Endothelial Transient Receptor Potential Channels and Vascular Remodeling: Extracellular Ca2 + Entry for Angiogenesis, Arteriogenesis and Vasculogenesis.

Authors:  Sharon Negri; Pawan Faris; Roberto Berra-Romani; Germano Guerra; Francesco Moccia
Journal:  Front Physiol       Date:  2020-01-21       Impact factor: 4.566

6.  Evaluation of FGFR1 as a diagnostic biomarker for ovarian cancer using TCGA and GEO datasets.

Authors:  Huiting Xiao; Kun Wang; Dan Li; Ke Wang; Min Yu
Journal:  PeerJ       Date:  2021-02-03       Impact factor: 2.984

Review 7.  Determinants of resistance to VEGF-TKI and immune checkpoint inhibitors in metastatic renal cell carcinoma.

Authors:  Prashanth Prithviraj; Nuzhat Ahmed; Revati Sharma; Elif Kadife; Mark Myers; George Kannourakis
Journal:  J Exp Clin Cancer Res       Date:  2021-06-07

8.  Molecular Protein and Expression Profile in the Primary Tumors of Clear Cell Renal Carcinoma and Metastases.

Authors:  Liudmila V Spirina; Zahar A Yurmazov; Alexey K Gorbunov; Evgeny A Usynin; Nadezhda A Lushnikova; Irina V Kovaleva
Journal:  Cells       Date:  2020-07-13       Impact factor: 7.666

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.